Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

The development and approval of tecoviromat (TPOXX®), the first antiviral against smallpox.

Merchlinsky M, Albright A, Olson V, Schiltz H, Merkeley T, Hughes C, Petersen B, Challberg M.

Antiviral Res. 2019 Aug;168:168-174. doi: 10.1016/j.antiviral.2019.06.005. Epub 2019 Jun 7. Review.

PMID:
31181284
2.

Rabbitpox in New Zealand White Rabbits: A Therapeutic Model for Evaluation of Poxvirus Medical Countermeasures Under the FDA Animal Rule.

Perry MR, Warren R, Merchlinsky M, Houchens C, Rogers JV.

Front Cell Infect Microbiol. 2018 Oct 5;8:356. doi: 10.3389/fcimb.2018.00356. eCollection 2018.

3.

Ectromelia Virus Disease Characterization in the BALB/c Mouse: A Surrogate Model for Assessment of Smallpox Medical Countermeasures.

Garver J, Weber L, Vela EM, Anderson M, Warren R, Merchlinsky M, Houchens C, Rogers JV.

Viruses. 2016 Jul 22;8(7). pii: E203. doi: 10.3390/v8070203.

4.

Effect of the deletion of genes encoding proteins of the extracellular virion form of vaccinia virus on vaccine immunogenicity and protective effectiveness in the mouse model.

Meseda CA, Campbell J, Kumar A, Garcia AD, Merchlinsky M, Weir JP.

PLoS One. 2013 Jun 13;8(6):e67984. doi: 10.1371/journal.pone.0067984. Print 2013.

5.

New neutralizing antibody epitopes in hepatitis C virus envelope glycoproteins are revealed by dissecting peptide recognition profiles.

Kachko A, Kochneva G, Sivolobova G, Grazhdantseva A, Lupan T, Zubkova I, Wells F, Merchlinsky M, Williams O, Watanabe H, Ivanova A, Shvalov A, Loktev V, Netesov S, Major ME.

Vaccine. 2011 Dec 9;30(1):69-77. doi: 10.1016/j.vaccine.2011.10.045. Epub 2011 Oct 29.

PMID:
22041300
6.

Passive immunotherapies protect WRvFire and IHD-J-Luc vaccinia virus-infected mice from lethality by reducing viral loads in the upper respiratory tract and internal organs.

Zaitseva M, Kapnick SM, Meseda CA, Shotwell E, King LR, Manischewitz J, Scott J, Kodihalli S, Merchlinsky M, Nielsen H, Lantto J, Weir JP, Golding H.

J Virol. 2011 Sep;85(17):9147-58. doi: 10.1128/JVI.00121-11. Epub 2011 Jun 29.

7.

Recombinant A27 protein synergizes with modified vaccinia Ankara in conferring protection against a lethal vaccinia virus challenge.

He Y, Meseda CA, Vassell RA, Merchlinsky M, Weir JP, Weiss CD.

Vaccine. 2010 Jan 8;28(3):699-706. doi: 10.1016/j.vaccine.2009.10.078. Epub 2009 Nov 1.

PMID:
19887133
8.

Comparative evaluation of the immune responses and protection engendered by LC16m8 and Dryvax smallpox vaccines in a mouse model.

Meseda CA, Mayer AE, Kumar A, Garcia AD, Campbell J, Listrani P, Manischewitz J, King LR, Golding H, Merchlinsky M, Weir JP.

Clin Vaccine Immunol. 2009 Sep;16(9):1261-71. doi: 10.1128/CVI.00040-09. Epub 2009 Jul 15.

9.

Smallpox vaccines induce antibodies to the immunomodulatory, secreted vaccinia virus complement control protein.

Adamo JE, Meseda CA, Weir JP, Merchlinsky MJ.

J Gen Virol. 2009 Nov;90(Pt 11):2604-8. doi: 10.1099/vir.0.008474-0. Epub 2009 Jul 8.

10.

Antibodies to the A27 protein of vaccinia virus neutralize and protect against infection but represent a minor component of Dryvax vaccine--induced immunity.

He Y, Manischewitz J, Meseda CA, Merchlinsky M, Vassell RA, Sirota L, Berkower I, Golding H, Weiss CD.

J Infect Dis. 2007 Oct 1;196(7):1026-32. Epub 2007 Aug 20.

PMID:
17763325
11.

Characterization and use of mammalian-expressed vaccinia virus extracellular membrane proteins for quantification of the humoral immune response to smallpox vaccines.

García AD, Meseda CA, Mayer AE, Kumar A, Merchlinsky M, Weir JP.

Clin Vaccine Immunol. 2007 Aug;14(8):1032-44. Epub 2007 Jun 27.

12.

Microarray assay for evaluation of the genetic stability of modified vaccinia virus Ankara B5R gene.

Laassri M, Meseda CA, Williams O, Merchlinsky M, Weir JP, Chumakov K.

J Med Virol. 2007 Jun;79(6):791-802.

PMID:
17457926
13.

CD4+ immune escape and subsequent T-cell failure following chimpanzee immunization against hepatitis C virus.

Puig M, Mihalik K, Tilton JC, Williams O, Merchlinsky M, Connors M, Feinstone SM, Major ME.

Hepatology. 2006 Sep;44(3):736-45.

PMID:
16941702
14.

Vaccinia virus nicking-joining enzyme is encoded by K4L (VACWR035).

Eckert D, Williams O, Meseda CA, Merchlinsky M.

J Virol. 2005 Dec;79(24):15084-90.

15.

Identification and preliminary characterization of vaccinia virus (Dryvax) antigens recognized by vaccinia immune globulin.

Jones-Trower A, Garcia A, Meseda CA, He Y, Weiss C, Kumar A, Weir JP, Merchlinsky M.

Virology. 2005 Dec 5;343(1):128-40. Epub 2005 Sep 13.

16.

Identification of a novel immunodominant cytotoxic T lymphocyte epitope derived from human factor VIII in a murine model of hemophilia A.

Wang W, Merchlinsky M, Inman J, Golding B.

Thromb Res. 2005;116(4):335-44. Epub 2005 Jan 21.

PMID:
16038719
17.

Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.

Meseda CA, Garcia AD, Kumar A, Mayer AE, Manischewitz J, King LR, Golding H, Merchlinsky M, Weir JP.

Virology. 2005 Sep 1;339(2):164-75.

18.

Mouse neurotoxicity test for vaccinia-based smallpox vaccines.

Li Z, Rubin SA, Taffs RE, Merchlinsky M, Ye Z, Carbone KM.

Vaccine. 2004 Mar 29;22(11-12):1486-93.

PMID:
15063573
19.

Development of a novel vaccinia-neutralization assay based on reporter-gene expression.

Manischewitz J, King LR, Bleckwenn NA, Shiloach J, Taffs R, Merchlinsky M, Eller N, Mikolajczyk MG, Clanton DJ, Monath T, Weltzin RA, Scott DE, Golding H.

J Infect Dis. 2003 Aug 1;188(3):440-8. Epub 2003 Jul 16.

PMID:
12870127
21.

Developing new smallpox vaccines.

Rosenthal SR, Merchlinsky M, Kleppinger C, Goldenthal KL.

Emerg Infect Dis. 2001 Nov-Dec;7(6):920-6.

22.

Vaccinia virus-bacteriophage T7 expression vector for complementation analysis of late gene processes.

Eckert D, Merchlinsky M.

J Gen Virol. 1999 Jun;80 ( Pt 6):1463-1469. doi: 10.1099/0022-1317-80-6-1463.

PMID:
10374964
23.

Vaccinia virus WR gene A5L is required for morphogenesis of mature virions.

Williams O, Wolffe EJ, Weisberg AS, Merchlinsky M.

J Virol. 1999 Jun;73(6):4590-9.

24.

Marker rescue of the host range restriction defects of modified vaccinia virus Ankara.

Wyatt LS, Carroll MW, Czerny CP, Merchlinsky M, Sisler JR, Moss B.

Virology. 1998 Nov 25;251(2):334-42.

25.
26.

Construction and characterization of vaccinia direct ligation vectors.

Merchlinsky M, Eckert D, Smith E, Zauderer M.

Virology. 1997 Nov 24;238(2):444-51.

27.

Introduction of foreign DNA into the vaccinia virus genome by in vitro ligation: recombination-independent selectable cloning vectors.

Merchlinsky M, Moss B.

Virology. 1992 Sep;190(1):522-6. Erratum in: Virology 1993 Feb;192(2):717.

PMID:
1529553
30.
32.
36.

Construction of an infectious molecular clone of the autonomous parvovirus minute virus of mice.

Merchlinsky MJ, Tattersall PJ, Leary JJ, Cotmore SF, Gardiner EM, Ward DC.

J Virol. 1983 Jul;47(1):227-32.

37.

The complete DNA sequence of minute virus of mice, an autonomous parvovirus.

Astell CR, Thomson M, Merchlinsky M, Ward DC.

Nucleic Acids Res. 1983 Feb 25;11(4):999-1018.

38.

17-Ketosteroids via a base induced cleavage of C-17-dihydroxy acetone side chains.

Simons SS Jr, Merchlinsky MJ, Johnson DF.

Steroids. 1981 Mar;37(3):281-9.

PMID:
7233455
39.

Synthesis and biological activity of some novel, chemically reactive glucocorticoids.

Simons SS Jr, Thompson EB, Merchlinsky MJ, Johnson DF.

J Steroid Biochem. 1980 Mar;13(3):311-22. No abstract available.

PMID:
7392608

Supplemental Content

Loading ...
Support Center